JP2017501205A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501205A5
JP2017501205A5 JP2016544593A JP2016544593A JP2017501205A5 JP 2017501205 A5 JP2017501205 A5 JP 2017501205A5 JP 2016544593 A JP2016544593 A JP 2016544593A JP 2016544593 A JP2016544593 A JP 2016544593A JP 2017501205 A5 JP2017501205 A5 JP 2017501205A5
Authority
JP
Japan
Prior art keywords
alkyl
halo
alkoxy
carbocyclyl
alkanoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016544593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501205A (ja
JP6759100B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/072851 external-priority patent/WO2015103317A1/en
Publication of JP2017501205A publication Critical patent/JP2017501205A/ja
Publication of JP2017501205A5 publication Critical patent/JP2017501205A5/ja
Application granted granted Critical
Publication of JP6759100B2 publication Critical patent/JP6759100B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016544593A 2013-12-30 2014-12-30 治療用阻害化合物 Expired - Fee Related JP6759100B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361921995P 2013-12-30 2013-12-30
US61/921,995 2013-12-30
US201462025203P 2014-07-16 2014-07-16
US62/025,203 2014-07-16
PCT/US2014/072851 WO2015103317A1 (en) 2013-12-30 2014-12-30 Therapeutic inhibitory compounds

Publications (3)

Publication Number Publication Date
JP2017501205A JP2017501205A (ja) 2017-01-12
JP2017501205A5 true JP2017501205A5 (https=) 2018-02-08
JP6759100B2 JP6759100B2 (ja) 2020-09-23

Family

ID=53493998

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016544593A Expired - Fee Related JP6759100B2 (ja) 2013-12-30 2014-12-30 治療用阻害化合物

Country Status (11)

Country Link
US (2) US10266515B2 (https=)
EP (1) EP3089746A4 (https=)
JP (1) JP6759100B2 (https=)
KR (1) KR20160106627A (https=)
CN (1) CN106061480B (https=)
AU (2) AU2014373735B2 (https=)
BR (1) BR112016015449A8 (https=)
CA (1) CA2935683A1 (https=)
EA (1) EA032713B1 (https=)
MX (1) MX2016008688A (https=)
WO (1) WO2015103317A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX353408B (es) 2010-04-22 2018-01-11 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
CA2920815C (en) 2013-08-14 2021-09-21 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
BR112016015449A8 (pt) * 2013-12-30 2020-06-09 Lifesci Pharmaceuticals Inc compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
US9611252B2 (en) * 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
RU2744460C2 (ru) 2014-04-15 2021-03-09 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости
MX381342B (es) * 2014-07-16 2025-03-12 Lifesci Pharmaceuticals Inc Compuestos terapeuticos inhibidores.
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
WO2017087885A1 (en) 2015-11-19 2017-05-26 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
WO2017122754A1 (ja) 2016-01-12 2017-07-20 日本ケミファ株式会社 電位依存性t型カルシウムチャネル阻害剤
IL263235B (en) 2016-05-31 2022-07-01 Kalvista Pharmaceuticals Ltd History of pyrazoles as plasma kallikrein inhibitors
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
CN110022875A (zh) 2016-07-11 2019-07-16 莱福斯希医药公司 治疗性抑制化合物
CN107033015B (zh) * 2017-06-02 2019-04-30 南京欧信医药技术有限公司 一种药物中间体的合成方法
HUE057912T2 (hu) 2017-11-29 2022-06-28 Kalvista Pharmaceuticals Ltd Plazma kallikrein inhibitort tartalmazó dózisformák
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2019152437A1 (en) 2018-01-30 2019-08-08 Foghorn Therapeutics Inc. Compounds and uses thereof
AU2019227866A1 (en) * 2018-02-28 2020-10-01 Attune Pharmaceuticals, Inc. Treatment of hereditary angioedema
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
KR20200143376A (ko) * 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
CN112867706B (zh) 2018-05-29 2024-11-15 奥默罗斯公司 Masp-2抑制剂和使用方法
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
WO2020160100A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
CN110256342B (zh) * 2019-07-16 2022-06-07 河南省科学院化学研究所有限公司 一种2-氰基喹啉衍生物的合成方法
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
CN114667289B (zh) 2019-09-18 2025-08-26 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
EP4031547B1 (en) 2019-09-18 2024-07-17 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof
IL293550A (en) 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
JP7699389B2 (ja) 2019-12-04 2025-06-27 オメロス コーポレーション Masp-2阻害剤および使用方法
EP4069676A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
CA3164134A1 (en) 2019-12-06 2021-06-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US20230121497A1 (en) * 2020-01-29 2023-04-20 Foghorn Therapeutics Inc. Compounds and uses thereof
CA3167275A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
JP2024509268A (ja) 2021-03-09 2024-02-29 フォグホーン セラピューティクス インコーポレイテッド 結晶形、それらを含有する組成物、及びそれらの使用方法
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
US12319655B2 (en) 2021-12-09 2025-06-03 Deciphera Pharmaceuticals, Llc RAF kinase inhibitors and methods of use thereof
JP2025531207A (ja) * 2022-09-15 2025-09-19 武田薬品工業株式会社 遺伝性血管性浮腫の処置のための血漿カリクレイン阻害剤としてのn-((イソキノリン-6イル)メチル)-1h-ピラゾール-4-カルボキサミド誘導体
WO2025001956A1 (zh) * 2023-06-30 2025-01-02 远森制药(杭州)有限公司 杂芳族甲酰胺类化合物及其在医药上的应用
WO2025160190A1 (en) * 2024-01-23 2025-07-31 Retune Pharma Inc. Therapeutic inhibitory compounds
WO2025247982A1 (en) * 2024-05-29 2025-12-04 Grünenthal GmbH Piperazines which act as sstr4 modulators

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW212792B (https=) * 1991-09-13 1993-09-11 Shell Internat Res Schappej B V
IL108459A0 (en) * 1993-02-05 1994-04-12 Opjohn Company 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
TW575562B (en) * 1998-02-19 2004-02-11 Agrevo Uk Ltd Fungicides
HK1045991B (en) * 1999-11-10 2004-12-10 Takeda Pharmaceutical Company Limited 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
NZ535985A (en) * 2002-03-29 2007-04-27 Chiron Corp Substituted benzazoles and use thereof as RAF kinase inhibitors
EP1603884A4 (en) * 2003-02-28 2008-05-28 Encysive Pharmaceuticals Inc PYRIDINE, PYRIMIDINE, QUINOLINE, QUINAZOLINE AND NAPHTHALENE UROTENSIN II RECEPTOR ANTAGONISTS
GB0403155D0 (en) * 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
JP2009520811A (ja) * 2005-12-22 2009-05-28 クリスタルジェノミクス、インコーポレイテッド プロテインキナーゼ活性を阻害するアミノピリミジン誘導体、及びその製造方法並びにこれを有効成分として含む医薬組成物
US20070254894A1 (en) * 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
WO2007098352A2 (en) 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
ES2396160T3 (es) * 2006-12-14 2013-02-19 Bayer Intellectual Property Gmbh Derivados de DIHIDROPIRIDINA que utiliza como inhibidores de la proteina quinasa
WO2008098978A2 (en) * 2007-02-16 2008-08-21 Glaxo Group Limited Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
WO2009083553A1 (en) 2007-12-31 2009-07-09 Rheoscience A/S Azine compounds as glucokinase activators
WO2009119088A1 (ja) * 2008-03-25 2009-10-01 武田薬品工業株式会社 複素環化合物
US20090270407A1 (en) * 2008-04-25 2009-10-29 E. I. Du Pont De Nemours And Company Fungicidal isoxazolidines
KR20110036044A (ko) 2008-07-18 2011-04-06 다케다 파머수티컬 컴패니 리미티드 벤즈아제핀 유도체들 및 히스타민 h3 길항제로서 이들의 용도
ES2534199T3 (es) 2008-10-31 2015-04-20 Merck Sharp & Dohme Corp. Antagonistas del receptor P2X3 para el tratamiento del dolor
EP2411384B1 (en) * 2009-03-26 2013-01-30 Syngenta Participations AG Insecticidal compounds
GB201004739D0 (en) * 2010-03-22 2010-05-05 Prosidion Ltd Receptor modulators
US9290485B2 (en) * 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
KR20180099933A (ko) * 2010-11-19 2018-09-05 리간드 파마슈티칼스 인코포레이티드 복소환 아민 및 이의 용도
GB201021103D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
CN102904742B (zh) 2011-07-29 2015-10-07 华为终端有限公司 对可执行节点的操作方法及系统
US20150017156A1 (en) * 2011-09-16 2015-01-15 The Ohio State University Esx-mediated transcription modulators and related methods
EP2780014A4 (en) * 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
EP2807156A1 (en) 2012-01-27 2014-12-03 Novartis AG Aminopyridine derivatives as plasma kallikrein inhibitors
US20140378474A1 (en) 2012-01-27 2014-12-25 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
CN104837818B (zh) 2012-12-07 2017-07-14 霍夫曼-拉罗奇有限公司 可用作cb2激动剂的吡啶‑2‑酰胺
MY174018A (en) 2013-05-23 2020-03-04 Kalvista Pharmaceuticals Ltd Heterocyclic derivates
CA2920815C (en) 2013-08-14 2021-09-21 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
BR112016015449A8 (pt) 2013-12-30 2020-06-09 Lifesci Pharmaceuticals Inc compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
US9611252B2 (en) * 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
MX381342B (es) * 2014-07-16 2025-03-12 Lifesci Pharmaceuticals Inc Compuestos terapeuticos inhibidores.
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
CN110022875A (zh) 2016-07-11 2019-07-16 莱福斯希医药公司 治疗性抑制化合物

Similar Documents

Publication Publication Date Title
JP2017501205A5 (https=)
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
CY1120342T1 (el) Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου
MX377635B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
JP2016513137A5 (https=)
HRP20211278T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
JP2016530283A5 (https=)
AR087545A1 (es) 1h-imidazo[4,5-c]quinolina sustituidos con actividad inhibitoria de bromodominio
JP2013510124A5 (https=)
IN2014MN02106A (https=)
CY1118721T1 (el) Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
CN107427516B8 (zh) 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
RU2013144571A (ru) Алинзамещенные хиназолины и способы их применения
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
CR20160527A (es) Derivados de carboxamida
WO2016127168A3 (en) Mebendazole polymorph for treatment and prevention of tumors
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto